Showing 4601-4610 of 5646 results for "".
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- CVP Welcomes Three New Ophthalmology Partner Practiceshttps://modernod.com/news/cvp-welcomes-three-new-ophthalmology-partner-practices/2478760/CVP has expanded its platform in the Midwest and Mid-Atlantic regions by adding three partner practices: Columbus Ophthalmology Associates (COA), Valley Eye Institute, near Dayton, Ohio; and Virginia Beach Eye Center. CVP now includes a network of nine partner pra
- US IDE Trial Results for Glaukos’ iStent infinite Show Reduction in IOPhttps://modernod.com/news/us-ide-trial-results-for-glaukos-istent-infinite-show-reduction-in-iop/2478754/Glaukos announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy
- EMA Receives Conditional Marketing Request for AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/ema-receives-conditional-marketing-request-for-astrazenecas-covid-19-vaccine/2478752/The European Medicines Agency announced Tuesday that it received an application for conditional marketing authorization of AstraZeneca and the University of Oxford’s COVID-19 vaccine AZD1222. The regulator noted that the vaccine will be reviewed under an accelerated timeline with an opinion
- Heidelberg Engineering Names New Clinical Directorhttps://modernod.com/news/heidelberg-engineering-names-new-clinical-director/2478749/Steve Thomson has joined Heidelberg Engineering as Clinical Director to further strengthen the anterior segment product development team, according to a company news release. He will concentrate
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e
- Bayer Strikes Alliance to Advance CureVac’s COVID-19 Vaccine CVnCoVhttps://modernod.com/news/bayer-strikes-alliance-to-advance-curevacs-covid-19-vaccine-cvncov/2478735/Bayer said that it has reached an agreement to further the development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. The companies indicated that they plan to combine their strengths for CureVac to be in a position to supply “hundreds of millions
- Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facilityhttps://modernod.com/news/adverum-biotechnologies-announces-new-gmp-gene-therapy-manufacturing-facility/2478734/Adverum Biotechnologies announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum will invest over $80 million in the 174,000-square-foot facility, located in Research Triangle Park (RTP). The site will include four 1,000-liter bioreactors, with space for